Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 plus Sintilimab in Advanced Biliary Tract Cancer
NCT05653180Phase 2Unknown
- Sponsor
- Innovent Biologics
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI310 in biliary tract cancer (BTC), sponsored by Innovent Biologics. Status: unknown.
02
Drugs
IBI310
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05653180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653180.